{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:41:46Z","timestamp":1793788906483,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012331","name":"LEO Fondet","doi-asserted-by":"publisher","award":["LF16115"],"award-info":[{"award-number":["LF16115"]}],"id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is linked with increased risk of cardiovascular disease (CVD) that is underestimated by traditional risk stratification. We conducted a large-scale plasma proteomic analysis by use of a proximity extension assay in 85 patients with a history of moderate-to-severe psoriasis with or without established atherosclerotic CVD. Differentially expressed proteins associated with CVD were correlated with subclinical atherosclerotic markers including vascular inflammation determined by<jats:sup>18<\/jats:sup>F-fluorodeoxyglucose positron emission tomography\/computed tomography, carotid intima-media thickness (CIMT), carotid artery plaques, and coronary artery calcium score (CCS) in the patients without CVD and statin treatment. We also examined the association between the neutrophil-to-lymphocyte ratio (NLR) and subclinical atherosclerosis. In unadjusted analyses, growth differentiation factor-15 (GDF-15) levels and NLR were increased, while tumor necrosis factor (TNF)-related activation-inducing ligand (TRANCE) and TNF-related apoptosis-induced ligand (TRAIL) levels were decreased in patients with established CVD compared to those without CVD. Among patients with psoriasis without CVD and statin treatment, GDF-15 levels were negatively associated with vascular inflammation in the ascending aorta and entire aorta, and positively associated with CIMT and CCS. NLR was positively associated with vascular inflammation in the carotid arteries. Our data suggest that circulating GDF-15 levels and NLR might serve as biomarkers of subclinical atherosclerosis in patients with psoriasis.<\/jats:p>","DOI":"10.1038\/s41598-021-00999-9","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T11:03:37Z","timestamp":1635851017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Biomarkers of subclinical atherosclerosis in patients with psoriasis"],"prefix":"10.1038","volume":"11","author":[{"given":"Hannah","family":"Kaiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kvist-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krakauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Michael","family":"G\u00f8rtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Riis","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke, W. H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front. Immunol. 9, 579 (2018).","journal-title":"Front. Immunol."},{"key":"999_CR2","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi, R. et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ 369, m1590 (2020).","journal-title":"BMJ"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong, E. J., Harskamp, C. T. & Armstrong, A. W. Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies. J. Am. Heart. Assoc. 2, e000062 (2013).","journal-title":"J. Am. Heart. Assoc."},{"key":"999_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/jdv.12523","volume":"29","author":"E Salahadeen","year":"2015","unstructured":"Salahadeen, E., Torp-Pedersen, C., Gislason, G., Hansen, P. R. & Ahlehoff, O. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 29, 1002\u20131005 (2015).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets, C. A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J. Am. Acad. Dermatol. 80, 1073\u20131113 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"999_CR6","first-page":"E1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, E1082\u2013E1143 (2019).","journal-title":"Circulation"},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/ijd.12196","volume":"53","author":"M Gyldenl\u00f8ve","year":"2014","unstructured":"Gyldenl\u00f8ve, M. et al. Psoriasis and the framingham risk score in a danish hospital cohort. Int. J. Dermatol. 53, 1086\u20131090 (2014).","journal-title":"Int. J. Dermatol."},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1136\/annrheumdis-2013-203433","volume":"73","author":"L Eder","year":"2014","unstructured":"Eder, L., Chandran, V. & Gladman, D. D. The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann. Rheum. Dis. 73, 1990\u20131996 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"999_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-020-02439-z","author":"W Zhou","year":"2020","unstructured":"Zhou, W. et al. The application of molecular imaging to advance translational research in chronic inflammation. J. Nucl. Cardiol. https:\/\/doi.org\/10.1007\/s12350-020-02439-z (2020).","journal-title":"J. Nucl. Cardiol."},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamacardio.2018.2769","volume":"3","author":"AA Joshi","year":"2018","unstructured":"Joshi, A. A. et al. Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. JAMA Cardiol. 3, 949\u2013956 (2018).","journal-title":"JAMA Cardiol."},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jcmg.2013.08.006","volume":"6","author":"AL Figueroa","year":"2013","unstructured":"Figueroa, A. L. et al. Measurement of arterial activity on routine FDG PET\/CT images improves prediction of risk of future CV events. JACC. Cardiovasc. Imaging 6, 1250\u20131259 (2013).","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bjd.15149","volume":"176","author":"KF Hjuler","year":"2017","unstructured":"Hjuler, K. F. et al. Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Br. J. Dermatol. 176, 732\u2013740 (2017).","journal-title":"Br. J. Dermatol."},{"key":"999_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000502138","volume":"235","author":"H Kaiser","year":"2019","unstructured":"Kaiser, H., Abdulla, J., Henningsen, K. M. A., Skov, L. & Hansen, P. R. Coronary artery disease assessed by computed tomography in patients with psoriasis: A systematic review and meta-analysis. Dermatology 235, 478\u2013487 (2019).","journal-title":"Dermatology"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2008.02936.x","volume":"23","author":"DD Balci","year":"2009","unstructured":"Balci, D. D. et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J. Eur. Acad. Dermatol. Venereol. 23, 1\u20136 (2009).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"999_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","volume":"119","author":"AA Joshi","year":"2016","unstructured":"Joshi, A. A. et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ. Res. 119, 1242\u20131253 (2016).","journal-title":"Circ. Res."},{"key":"999_CR16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/bjd.12525","volume":"169","author":"I Balta","year":"2013","unstructured":"Balta, I. et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. Br. J. Dermatol. 169, 1066\u20131070 (2013).","journal-title":"Br. J. Dermatol."},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11010-014-2277-y","volume":"400","author":"G Erfan","year":"2015","unstructured":"Erfan, G. et al. Serum YKL-40: A potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol. Cell. Biochem. 400, 207\u2013212 (2015).","journal-title":"Mol. Cell. Biochem."},{"key":"999_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaad.2014.06.006","volume":"71","author":"RM Robati","year":"2014","unstructured":"Robati, R. M., Partovi-Kia, M., Haghighatkhah, H. R., Younespour, S. & Abdollahimajd, F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis? J. Am. Acad. Dermatol. 71, 642\u2013648 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"999_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","volume":"84","author":"YA Elnabawi","year":"2021","unstructured":"Elnabawi, Y. A. et al. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. J. Am. Acad. Dermatol. 84, 913\u2013920 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"999_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","volume":"42","author":"NH Adamstein","year":"2021","unstructured":"Adamstein, N. H. et al. The neutrophil\u2013lymphocyte ratio and incident atherosclerotic events: Analyses from five contemporary randomized trials. Eur. Heart J. 42, 896\u2013903 (2021).","journal-title":"Eur. Heart J."},{"key":"999_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10238-018-0538-x","volume":"19","author":"P Paliogiannis","year":"2019","unstructured":"Paliogiannis, P. et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: A systematic review and meta-analysis. Clin. Exp. Med. 19, 37\u201345 (2019).","journal-title":"Clin. Exp. Med."},{"key":"999_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jcct.2020.12.006","volume":"15","author":"AK Dey","year":"2021","unstructured":"Dey, A. K. et al. Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. J. Cardiovasc. Comput. Tomogr. 15, 372\u2013379 (2021).","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"999_CR23","doi-asserted-by":"publisher","first-page":"e28669","DOI":"10.2196\/28669","volume":"10","author":"H Kaiser","year":"2021","unstructured":"Kaiser, H. et al. Multiscale biology of cardiovascular risk in psoriasis: Protocol for a case-control study. JMIR Res. Protoc. 10, e28669 (2021).","journal-title":"JMIR Res. Protoc."},{"key":"999_CR24","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014).","journal-title":"PLoS ONE"},{"key":"999_CR25","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","volume":"7","author":"PM Brunner","year":"2017","unstructured":"Brunner, P. M. et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci. Rep. 7, 8707 (2017).","journal-title":"Sci. Rep."},{"key":"999_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s00259-015-3259-3","volume":"43","author":"J Bucerius","year":"2016","unstructured":"Bucerius, J. et al. Position paper of the cardiovascular committee of the european association of nuclear medicine (EANM) on PET imaging of atherosclerosis. Eur. J. Nucl. Med. Mol. Imaging 43, 780\u2013792 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"999_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","volume":"15","author":"AS Agatston","year":"1990","unstructured":"Agatston, A. S. et al. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 15, 827\u2013832 (1990).","journal-title":"J. Am. Coll. Cardiol."},{"key":"999_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000343145","volume":"34","author":"P-J Touboul","year":"2012","unstructured":"Touboul, P.-J. et al. Mannheim carotid intima-media thickness and plaque consensus (2004\u20132006\u20132011). Cerebrovasc. Dis. 34, 290\u2013296 (2012).","journal-title":"Cerebrovasc. Dis."},{"key":"999_CR29","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"999_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"999_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jcmg.2012.06.006","volume":"5","author":"ZH Hou","year":"2012","unstructured":"Hou, Z. H. et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc. Imaging 5, 990\u2013999 (2012).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"999_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff, D. C. et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology\/American heart association task force on practice guidelines. Circulation 129, 49\u201373 (2014).","journal-title":"Circulation"},{"key":"999_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bjd.12355","volume":"169","author":"EA Dowlatshahi","year":"2013","unstructured":"Dowlatshahi, E. A., Van Der Voort, E. A. M., Arends, L. R. & Nijsten, T. Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis. Br. J. Dermatol. 169, 266\u2013282 (2013).","journal-title":"Br. J. Dermatol."},{"key":"999_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"W-H Boehncke","year":"2011","unstructured":"Boehncke, W.-H., Boehncke, S., Tobin, A.-M. & Kirby, B. The \u2018psoriatic march\u2019: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 20, 303\u2013307 (2011).","journal-title":"Exp. Dermatol."},{"key":"999_CR35","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.ijbiomac.2018.07.021","volume":"118","author":"K Yadav","year":"2018","unstructured":"Yadav, K., Singh, D. & Singh, M. R. Protein biomarker for psoriasis: A systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis. Int. J. Biol. Macromol. 118, 1796\u20131810 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"999_CR36","doi-asserted-by":"publisher","first-page":"e012826","DOI":"10.1161\/JAHA.119.012826","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang, J., Wei, L., Yang, X. & Zhong, J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J. Am. Heart Assoc. 8, e012826 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"999_CR37","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/eurheartj\/ehq077","volume":"31","author":"S Taddei","year":"2010","unstructured":"Taddei, S. & Virdis, A. Growth differentiation factor-15 and cardiovascular dysfunction and disease: Malefactor or innocent bystander? Eur. Heart J. 31, 1168\u20131171 (2010).","journal-title":"Eur. Heart J."},{"key":"999_CR38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.106.650846","volume":"115","author":"KC Wollert","year":"2007","unstructured":"Wollert, K. C. et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115, 962\u2013971 (2007).","journal-title":"Circulation"},{"key":"999_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/eurheartj\/ehn600","volume":"30","author":"SQ Khan","year":"2009","unstructured":"Khan, S. Q. et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur. Heart J. 30, 1057\u20131065 (2009).","journal-title":"Eur. Heart J."},{"key":"999_CR40","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/eurheartj\/ehp261","volume":"30","author":"L Lind","year":"2009","unstructured":"Lind, L. et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: Results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Eur. Heart J. 30, 2346\u20132353 (2009).","journal-title":"Eur. Heart J."},{"key":"999_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1373\/clinchem.2011.171926","volume":"58","author":"A Rohatgi","year":"2012","unstructured":"Rohatgi, A. et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: Observations from the dallas heart study. Clin. Chem. 58, 172\u2013182 (2012).","journal-title":"Clin. Chem."},{"key":"999_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.carpath.2012.02.003","volume":"21","author":"H Johnen","year":"2012","unstructured":"Johnen, H. et al. Increased expression of the TGF-b superfamily cytokine MIC-1\/GDF15 protects ApoE\u2212\/\u2212 mice from the development of atherosclerosis. Cardiovasc. Pathol. 21, 499\u2013505 (2012).","journal-title":"Cardiovasc. Pathol."},{"key":"999_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3346\/jkms.2016.31.9.1413","volume":"31","author":"MY Shin","year":"2016","unstructured":"Shin, M. Y. et al. Association between growth differentiation factor 15 (GDF15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J. Korean Med. Sci. 31, 1413\u20131418 (2016).","journal-title":"J. Korean Med. Sci."},{"key":"999_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","volume":"31","author":"MP Bonaca","year":"2011","unstructured":"Bonaca, M. P. et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: Observations from PROVE IT-TIMI 22. Arterioscler. Thromb. Vasc. Biol. 31, 203\u2013210 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"999_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4093\/dmj.2016.40.1.70","volume":"40","author":"JM Kim","year":"2016","unstructured":"Kim, J. M. et al. Effect of atorvastatin on growth differentiation factor-15 in patients with type 2 diabetes mellitus and dyslipidemia. Diabetes Metab. J. 40, 70\u201378 (2016).","journal-title":"Diabetes Metab. J."},{"key":"999_CR46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2174\/138161212799504803","volume":"18","author":"S Antonopoulos","year":"2012","unstructured":"Antonopoulos, S., Margaritis, M., Lee, R., Channon, K. & Antoniades, C. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 18, 1519\u20131530 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"999_CR47","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jacc.2019.06.057","volume":"74","author":"RH Al-Mashhadi","year":"2019","unstructured":"Al-Mashhadi, R. H. et al. 18Fluorodeoxyglucose accumulation in arterial tissues determined by PET signal analysis. J. Am. Coll. Cardiol. 74, 1220\u20131232 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"999_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1752854","author":"S Bernardi","year":"2016","unstructured":"Bernardi, S., Bossi, F., Toffoli, B. & Fabris, B. Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease. BioMed. Res. Int. https:\/\/doi.org\/10.1155\/2016\/1752854 (2016).","journal-title":"BioMed. Res. Int."},{"key":"999_CR49","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1111\/ijd.13159","volume":"55","author":"TE Amin","year":"2016","unstructured":"Amin, T. E. et al. Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis. Int. J. Dermatol. 55, e227\u2013e233 (2016).","journal-title":"Int. J. Dermatol."},{"key":"999_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00223-013-9712-z","volume":"93","author":"M Wu","year":"2013","unstructured":"Wu, M., Rementer, C. & Giachelli, C. M. Challenges in treatment. Calcif. Tissue Int. 93, 365\u2013373 (2013).","journal-title":"Calcif. Tissue Int."},{"key":"999_CR51","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaci.2010.03.018","volume":"125","author":"LC Zaba","year":"2010","unstructured":"Zaba, L. C. et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J. Allergy Clin. Immunol. 125, 1261 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"999_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/EJE-08-0554","volume":"159","author":"M Nybo","year":"2008","unstructured":"Nybo, M. & Rasmussen, L. M. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur. J. Endocrinol. 159, 603\u2013608 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"999_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1155\/2020\/3709749","volume":"2020","author":"WM Wang","year":"2020","unstructured":"Wang, W. M. & Jin, H. Z. Role of neutrophils in psoriasis. J. Immunol. Res. 2020, 18\u201323 (2020).","journal-title":"J. Immunol. Res."},{"key":"999_CR54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/echo.12511","volume":"31","author":"M Yurtda\u015f","year":"2014","unstructured":"Yurtda\u015f, M. et al. Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echocardiography 31, 1095\u20131104 (2014).","journal-title":"Echocardiography"},{"key":"999_CR55","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","volume":"35","author":"HB Naik","year":"2015","unstructured":"Naik, H. B. et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study. Arterioscler. Thromb. Vasc. Biol. 35, 2667\u20132676 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"999_CR56","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/01.CIR.0000042674.89762.20","volume":"106","author":"T Naruko","year":"2002","unstructured":"Naruko, T. et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106, 2894\u20132900 (2002).","journal-title":"Circulation"},{"key":"999_CR57","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jcmg.2016.04.007","volume":"9","author":"FM Van der Valk","year":"2016","unstructured":"Van der Valk, F. M. et al. Thresholds for arterial wall inflammation quantified by 18F-FDG PET imaging: Implications for vascular interventional studies. JACC Cardiovasc. Imaging 9, 1198\u20131207 (2016).","journal-title":"JACC Cardiovasc. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00999-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:41:53Z","timestamp":1726044113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00999-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00999-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"6 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R.H. is recipient of a Borregaard Clinical Scientist Fellowship from the NOVO Nordisk Foundation and chairs a clinical academic group supported by the Greater Region of Copenhagen Health Science Partners. C.B. is a consultant for Onegevity Health. L.S. has been a paid speaker for Eli Lilly, AbbVie and LEO Pharma, and has been a consultant or served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Admirall and Sanofi. She has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag and Leo Pharma. H.K., X.W., A.K-H., M.K., P.M.G and B.M have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21438"}}